There are still a lot of challenges facing pharmaceuticals, med tech, and biotech companies that seek to begin a clinical trial post-COVID. But the obstacles aren’t stopping them. At time of writing, over 500 companies have a Phase II or Phase III clinical trial startup planned in the next 12
The decentralized clinical trial is one of the most talked-about emerging trends in the life sciences industry. These sorts of clinical trials present immense benefits, as we wrote about in a recent blog.
If executed well, the decentralized clinical trial design could both reduce resource consumption and accelerate treatments arrival to
Increased diversity. Faster enrollment. Reduction in costs. These are just a few of the myriad benefits of the virtual clinical trial touted by CROs and solution providers. But are you ready for a truly virtual clinical trial? If not, is a hybrid clinical trial realistic? And what is a decentralized
We recently spoke with Liz Beatty, Chief Strategy Officer at Inato about how the company is disrupting the industry's approach to site selection. The company is headquartered in Paris, France, with US operations based in New York City, NY. Here are some of the most interesting excerpts from our discussion:
Choosing the right way to train clinical trial staff is complex and exhausting under normal circumstances. Today’s immense pressure to accommodate new virtual working styles across investigator meetings, site selection, and site initiation visits magnifies those challenges.
As we revealed in our recent report, clinical operations leaders are adopting virtual tools
We recently spoke about virtual and hybrid clinical trials with Amy O’Sullivan, Director of North American Operations at SCOPE International, an independent full-service CRO serving pharma, biotech, and medical device clients across the US and Europe. The company is headquartered in Mannheim, Germany, with US operations based in Pittsburgh, PA.
Today, ArcheMedX, a leader in behavior-based learning and operational insights for life sciences and healthcare organizations, announced the results of its new survey, “COVID-19's Impact on Virtual Tech in Clinical Trials.” The findings reveal brand-new insights into how clinical trial leaders in pharmaceuticals, biotech, and clinical research organizations are accelerating
Making it through the clinical trial start-up process is critical for any study - and takes a lot of effort under normal circumstances. But today, with the need to conduct more and more clinical operations remotely - it’s even more challenging.
The good news is that there is a way forward,